|
Re: TDM-1 results reported @ ASCO annual mtg 2012 now in New England Journal of Medic
Actually, this article (and the full article seems to be available for free) updates the ASCO data, and includes the significant point that T-DM1 improves overall survival over Tykerb and Xeloda by almost 6 months. Very impressive! Genentech says it anticipates approval of T-DM1 by the end of February 2013. The updated data was presented at the ESMO conference.
|
Threaded Mode